Neutrophil count is associated with myeloid derived suppressor cell level and presents prognostic value of for hepatocellular carcinoma patients

Oncotarget

Volumn 8, Issue 15, 2017, Pages 24380-24388

  Li, Xing ^a,b   Xing, Yan Fang ^c   Lei, Ai Hua ^a   Xiao, Qiang ^a   Lin, Zhi Huan ^b   Hong, Ying Fen ^b   Wu, Xiang Yuan ^b   Zhou, Jie ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Myeloid derived suppressor cell; Neutrophil counts; Patient selection; Prognosis

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYELOID-DERIVED SUPPRESSOR CELL; NEUTROPHIL; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOCYTE COUNT; BLOOD; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUTROPHILS; PROGNOSIS;

EID: 85017566039     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15456     Document Type: Article

References (24)

1. Hu CE, Gan J, Zhang RD, Cheng YR, Huang GJ. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol. 2011; 46:156-164
2. Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013; 73:2435-2444
3. Chiu DK, Xu IM, Lai RK, Tse AP, Wei LL, Koh HY, Li LL, Lee D, Lo RC, Wong CM, Ng IO, Wong CC. Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26. Hepatology. 2016; 64:797-813
4. Wang D, An G, Xie S, Yao Y, Feng G. The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. Tumour Biol. 2016; 37:10427-10433
5. Gao XH, Tian L, Wu J, Ma XL, Zhang CY, Zhou Y, Sun YF, Hu B, Qiu SJ, Zhou J, Fan J, Guo W, Yang XR. Circulating CD14+ HLA-DR-/low myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. Hepatol Res. 2016
6. Mizukoshi E, Yamashita T, Arai K, Terashima T, Kitahara M, Nakagawa H, Iida N, Fushimi K, Kaneko S. Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Immunol Immunother. 2016; 65:715-725
7. Grutzner E, Stirner R, Arenz L, Athanasoulia AP, Schrodl K, Berking C, Bogner JR, Draenert R. Kinetics of human myeloid-derived suppressor cells after blood draw. J Transl Med. 2016; 14:2
8. Li X, Chen ZH, Ma XK, Chen J, Wu DH, Lin Q, Dong M, Wei L, Wang TT, Ruan DY, Lin ZX, Xing YF, Deng Y, et al. Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol. 2014; 35:11057-11063
9. Lin ZX, Ruan DY, Li Y, Wu DH, Ma XK, Chen J, Chen ZH, Li X, Wang TT, Lin Q, Wen JY, Wu XY. Lymphocyteto-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection. World J Gastroenterol. 2015; 21:10898-10906
10. Li X, Chen ZH, Xing YF, Wang TT, Wu DH, Wen JY, Chen J, Lin Q, Dong M, Wei L, Ruan DY, Lin ZX, Wu XY, et al. Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma. Tumour Biol. 2015; 36:2263-2269
11. Lin ZH, Li X, Hong YF, Ma XK, Wu DH, Huang M, Chen ZH, Chen J, Dong M, Wei L, Wang TT, Ruan DY, Lin ZX, et al. Alanine aminotransferase to hemoglobin ratio is an indicator for disease progression for hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization. Tumour Biol. 2016; 37:2951-2959
12. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013; 13:739-752
13. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016; 7:12150
14. Li X, Dong M, Lin Q, Chen ZH, Ma XK, Xing YF, Wan XB, Wen JY, Wei L, Chen J, Wu XY. Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials. Asia Pac J Clin Oncol. 2013; 9:86-92
15. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015; 33:2753-2762
16. Hyman DM, Solit DB, Arcila ME, Cheng DT, Sabbatini P, Baselga J, Berger MF, Ladanyi M. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today. 2015; 20:1422-1428
17. Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol. 2013; 3:49
18. Gao Q, Wang XY, Zhou J, Fan J. Heterogeneity of intermediatestage HCC necessitates personalized management including surgery. Nat Rev Clin Oncol. 2015; 12:10
19. Nault JC, Villanueva A. Intratumor molecular and phenotypic diversity in hepatocellular carcinoma. Clin Cancer Res. 2015; 21:1786-1788
20. Jeng KS, Chang CF, Jeng WJ, Sheen IS, Jeng CJ. Heterogeneity of hepatocellular carcinoma contributes to cancer progression. Crit Rev Oncol Hematol. 2015; 94:337-347
21. Gong Y, Koh DR. Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model. Cell Tissue Res. 2010; 339:437-448
22. Neagoe PE, Brkovic A, Hajjar F, Sirois MG. Expression and release of angiopoietin-1 from human neutrophils: intracellular mechanisms. Growth Factors. 2009; 27:335-344
23. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol. 2016; 37:208-220
24. Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang XW, Fan J, Zhou J. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology. 2012; 56:2242-2254